Core IM | Internal Medicine Podcast #197 Hypercoagulability Part 2: 5 Pearls Segment
70 snips
Jan 7, 2026 Dive into the gray areas of VTE management! Discover how to determine anticoagulation duration for different types of clots. Learn about the significance of dose-reduced DOACs and what constitutes true DOAC failure. The discussion highlights antiphospholipid syndrome as a critical diagnosis that can shift treatment strategies. Explore detailed case examples involving cancer-related clots and travel-induced DVTs, emphasizing personalized risk assessments and practical takeaways in anticoagulation care.
AI Snips
Chapters
Transcript
Episode notes
Customize Anticoagulation Duration
- Assess anticoagulation duration by combining clot clinical risk (size/location) and recurrence risk.
- For high bleeding risk or older patients, finish full-dose then continue a dose-reduced DOAC for long-term prevention.
Distal DVTs Have Lower Recurrence
- Distal (below-knee) DVTs carry about half the recurrence risk of proximal DVTs.
- That lower risk supports shorter anticoagulation courses for low-risk unprovoked distal clots.
Use Dose‑Reduced DOACs For Secondary Prevention
- After an initial 3–6 month full-dose period, consider low-dose apixaban (2.5 mg BID) or rivaroxaban (10 mg daily) for indefinite secondary prevention.
- Trials (AMPLIFY-EXTEND, EINSTEIN-CHOICE, APICAT) show reduced recurrence with similar or lower bleeding versus full dose.